GSK’s Withdrawn Blood Cancer Drug Poised for Comeback

GSK Plc said a blood cancer drug it had to pull from the market after a trial failure has shown promising results when combined with another cancer treatment.

Study data show that Blenrep, when taken with PomDex, nearly halved relapsed multiple myeloma patients’ risk of disease progression or death, marking a potential comeback for the treatment.

The data, presented Sunday at the American Society of Clinical Oncology conference, found that patients taking the drug combination didn’t have disease progression at 21.8 months, while those not on the treatment saw their disease advance at 12.7 months.

Blenrep is part of the ...